Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening

Clinical Microbiology and Infection

Volumn 19, Issue 3, 2013, Pages 266-272

  Hu, H ^a,b   Harmer, C ^a   Anuj, S ^c   Wainwright, C E ^c   Manos, J ^a   Cheney, J ^c   Harbour, C ^a   Zablotska, I ^d   Turnbull, L ^e   Whitchurch, C B ^e   Grimwood, K ^c   Rose, B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Child; Cystic fibrosis; Phenotype; Pseudomonas aeruginosa; Type 3 secreting system

Indexed keywords

ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; COMPARATIVE STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; GENDER; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEWBORN SCREENING; NONHUMAN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; TYPE III SECRETION SYSTEM; WESTERN BLOTTING;

PSEUDOMONAS AERUGINOSA;

EID: 84874320329     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03770.x     Document Type: Article

References (29)

1. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299-323.
2. Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 2010; 11: 177-184.
3. Marshall BC, Hazle L. Cystic Fibrosis Foundation Patient Registry 2009, annual data report (2011) Bethesda, MD: Cystic Fibrosis Foundation.
4. Hassett DJ, Korfhagen TR, Irvin RT et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 2010; 14: 117-130.
5. Schulert GS, Feltman H, Rabin SD et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003; 188: 1695-1706.
6. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004; 72: 6969-6977.
7. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol 2009; 12: 61-66.
8. Hauser AR. The type III secretion system of Pseudomonas aeruginosa:infection by injection. Nat Rev Microbiol 2009; 7: 654-665.
9. Lee VT, Smith RS, Tummler B, Lory S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 2005; 73: 1695-1705.
10. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147: 2659-2669.
11. Jain M, Ramirez D, Seshadri R et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004; 42: 5229-5237.
12. Wareham DW, Curtis MA. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Med Microbiol 2007; 297: 227-234.
13. Jain M, Bar-Meir M, McColley S et al. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. Transl Res 2008; 152: 257-264.
14. Wainwright CE, Vidmar S, Armstrong DS et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011; 306: 163-171.
15. Kidd TJ, Ramsay KA, Hu H et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol 2009; 47: 1503-1509.
16. Anuj SN, Whiley DM, Kidd TJ et al. Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009; 63: 127-131.
17. Anthony M, Rose B, Pegler MB et al. Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol 2002; 40: 2772-2778.
18. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
19. Ajayi T, Allmond LR, Sawa T, Wiener-Kronish JP. Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol 2003; 41: 3526-3531.
20. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-964.
21. Tan MW, Rahme LG, Sternberg JA, Tompkins RG, Ausubel FM. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A 1999; 96: 2408-2413.
22. Li L, Ledizet M, Kar K, Koski RA, Kazmierczak BI. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrob 2005; 4: 22.
23. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004; 145: 32-38.
24. Griffiths AL, Jamsen K, Carlin JB et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 2005; 171: 1020-1025.
25. O'Carroll MR, Syrmis MW, Wainwright CE et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004; 24: 101-106.
26. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183: 444-452.
27. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-530.
28. Grimwood K, Semple RA, Rabin HR, Sokol PA, Woods DE. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol 1993; 15: 135-139.
29. Roy-Burman A, Savel RH, Racine S et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183: 1767-1774.